Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10962407 | 0.86 | ATM (0.37) | MAPTPOLBMITFATMALDH1A1 | |
| Water SCHEMBL3197097 | 0.75 | CYP1A2 (0.38) | — | |
| SCHEMBL5353581 | 0.73 | MITF (0.46) | MAPTPOLBMITFALDH1A1LMNA | |
| SCHEMBL21291552 | 0.72 | GAA (0.37) | MAPTPOLBMITFALDH1A1LMNA | |
| SCHEMBL5140262 | 0.71 | L3MBTL1 (0.40) | MITFALDH1A1LMNAL3MBTL1KDM4E | |
| SCHEMBL11778385 | 0.69 | KDM4E (0.33) | MAPTMITFALDH1A1KDM4EKMT2A | |
| SCHEMBL5140534 | 0.68 | MITF (0.49) | MAPTPOLBMITFALDH1A1LMNA | |
| SCHEMBL5035092 | 0.68 | ALDH1A1 (0.45) | MAPTPOLBMITFATMALDH1A1 | |
| SCHEMBL31483563 | 0.67 | — | — | |
| SCHEMBL20744219 | 0.67 | KDM4E (0.33) | POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011348-A1 | Synthesis Process of X-IPM, Stable Crystal Form and Application Thereof | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2025-01-09 | — | — | US | disclosed |
| CN-117105975-A | X-IPM synthesis process, stable crystal form and application thereof | 深圳艾欣达伟医药科技有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-2336141-B1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9226932-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| CN-102746336-B | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2015-08-19 | — | — | CN | disclosed |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8664204-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | disclosed |
| US-8507464-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| CN-102746336-A | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS INC | 2012-10-24 | — | — | CN | disclosed |
| CN-101501054-B | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS INC | 2012-09-05 | — | — | CN | disclosed |
| EP-1896040-B1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110251159-A1 | Phosphoramidate Alkylator Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-8003625-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2336141-A2 | Phosphoramidate alkylator prodrugs | Threshold Pharmaceuticals, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | IMMUNOGENESIS, INC. | 2010-06-03 | — | — | US | disclosed |
| CN-101501054-A | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS INC (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-1896040-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | Threshold Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007002931-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2005086951-A2 | HYPOXIA-ACTIVATED ANTI-CANCER AGENTS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | TYMP, PAICS, PNP | MAPT 4106/4885POLB 779/4885MITF 4354/4885 |
| US-20250011348-A1 | Synthesis Process of X-IPM, Stable Crystal Form and Application Thereof | CHRM2, CHRM1, INMT | MAPT 4215/4885POLB 2196/4885MITF 257/4885 |
| US-20110251159-A1 | Phosphoramidate Alkylator Prodrugs | TYMP, PAICS, PNP | MAPT 4228/4885POLB 746/4885MITF 4387/4885 |
| US-20140170240-A1 | Phosphoramidate Alkylator Prodrugs | TYMP, PAICS, PNP | MAPT 4228/4885POLB 746/4885MITF 4387/4885 |
| US-20130303778-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | TYMP, PAICS, PNP | MAPT 4228/4885POLB 746/4885MITF 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.